Treatment of cardiac risk factors among patients with schizophrenia and diabetes.

Weiss AP, Henderson DC, Weilburg JB, Goff DC, Meigs JB, Cagliero E, et al. Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatr Serv. 2006;57(8):1145-52. DOI: 10.1176/ps.2006.57.8.1145. PubMed PMID: 16870966.

A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses.

Dixon LB, Kreyenbuhl JA, Dickerson FB, Donner TW, Brown CH, Wohlheiter K, et al. A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses. Psychiatr Serv. 2004;55(8):892-900. DOI: 10.1176/appi.ps.55.8.892. PubMed PMID: 15292539.

Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness.

Kreyenbuhl J, Dickerson FB, Medoff DR, Brown CH, Goldberg RW, Fang LJ, et al. Extent and management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness. J Nerv Ment Dis. 2006;194(6):404-10. DOI: 10.1097/01.nmd.0000221177.51089.7d. PubMed PMID: 16772856; PubMed Central PMCID: PMC3673558.

A Case of Mutism in Noncatatonic Schizophrenia Responding to Small Dose of Fluvoxamine Addition to Clozapine.

Hirakawa H, Terao T, Tanaka T, Sato H, Yoshimura R. A Case of Mutism in Noncatatonic Schizophrenia Responding to Small Dose of Fluvoxamine Addition to Clozapine. J Clin Psychopharmacol. 2016;36(5):531-2. DOI: 10.1097/JCP.0000000000000552. PubMed PMID: 27508430.

Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole.

Jakobsen KD, Bruhn CH, Pagsberg A-K, Fink-Jensen A, Nielsen J. Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole. J Clin Psychopharmacol. 2016;36(5):496-9. DOI: 10.1097/JCP.0000000000000548. PubMed PMID: 27504593.

Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.

Loebel A, Silva R, Goldman R, Watabe K, Cucchiaro J, Citrome L, et al. Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study. J Clin Psychiatry. 2016;77(12):1672-1680. DOI: 10.4088/JCP.16m10698. PubMed PMID: 27454547.

Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1: Magnitude and Moderators of the Problem.

Andrade C. Cardiometabolic Risks in Schizophrenia and Directions for Intervention, 1: Magnitude and Moderators of the Problem. J Clin Psychiatry. 2016;77(7):e844-7. DOI: 10.4088/JCP.16f10997. PubMed PMID: 27464317.

D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.

Goff DC. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia. Schizophrenia Bulletin. 2012;38(5):936-41. DOI: 10.1093/schbul/sbs012. PubMed PMID: 22368237; PubMed Central PMCID: PMC3446239.

Pathological Basis for Deficient Excitatory Drive to Cortical Parvalbumin Interneurons in Schizophrenia.

Chung DW, Fish KN, Lewis DA. Pathological Basis for Deficient Excitatory Drive to Cortical Parvalbumin Interneurons in Schizophrenia. Am J Psychiatry. 2016;173(11):1131-1139. DOI: 10.1176/appi.ajp.2016.16010025. PubMed PMID: 27444795.

Psychotic disorders in DSM-5 and ICD-11.

Biedermann F, Fleischhacker WW. Psychotic disorders in DSM-5 and ICD-11. CNS Spectr. 2016;21(4):349-54. DOI: 10.1017/S1092852916000316. PubMed PMID: 27418328.